Litcius/Paper detail

COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?

Oronzo Brunetti, Afshin Derakhshani, Behzad Baradaran, Antonio Galvano, Antonio Russo, Nicola Silvestris

2020Frontiers in Oncology43 citationsDOIOpen Access PDF

Abstract

The world is facing a new pandemic caused by a novel beta coronavirus (COVID 19), which causes severe respiratory coronavirus syndrome (SARS-CoV-2). Unfortunately, there are currently no US Food and Drug Administration (FDA) approved medications for the treatment of COVID-19 patients. High mortality rates in frail patients is a notable feature of the virus registered since the onset of COVID-19 pandemic. Above all, elderly patients or those with underlying chronic illnesses and compromised immune system are most at risk (1). Thus, the consideration is that the possible coexistence, in the same individual, of a cancer diagnosis and a COVID-19 infection could generate a synergistic negative prognostic effect.

Topics & Concepts

Coronavirus disease 2019 (COVID-19)EpidemiologyMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCancerIntensive care medicineOncologyInternal medicineVirologyDiseaseOutbreakInfectious disease (medical specialty)COVID-19 and healthcare impactsCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? | Litcius